Karmanos Cancer Institute/Wayne State University

Detroit, Michigan 48209

0 studies enrolling now · 34 studies all time

What they study most

Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Advanced Non-clear Cell Renal Cell Carcinoma, Anaplastic Large Cell Lymphoma, Biliary Tract Cancer, Breast Neoplasms, Carcinoma, Non Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Transitional Cell

Studies at this site

• A Long-term Extension Study of PCI-32765 (Ibrutinib) — Recruiting now
• PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer — Running, not enrolling
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma — Stopped early
• Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab — Stopped early
• Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer — Completed
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer — Completed
• A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) — Completed
• A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma — Stopped early
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) — Completed
• A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) — Completed
• Safety Study of SEA-CD40 in Cancer Patients — Stopped early
• A Safety Study of SGN-LIV1A in Breast Cancer Patients — Completed
• Selinexor Treatment of Refractory Myeloma — Completed
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma — Completed
• 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy — Completed
• Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer — Completed
• Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) — Completed
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) — Completed
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer — Completed
• A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma — Stopped early
• A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors — Stopped early
• PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib — Completed
• A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML — Completed
• Safety Study of SGN-CD70A in Cancer Patients — Completed
• Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma — Completed
• A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma — Completed
• A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study — Completed
• Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) — Completed
• A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma — Completed
• Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) — Completed
• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma — Stopped early
• A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma — Stopped early
• Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen — Completed
• PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy — Status unconfirmed